إعلان
إعلان
ALLO
Allogene Therapeutics, Inc. Common Stock
1.71
USDبرعاية
+0.22
+15.03%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
1.72
+0.01
+0.35%
تقارير أرباح ALLO
النسبة الإيجابية المفاجئة
ALLO تفوق 26 من 29 آخر التقديرات.
90%
التقرير التالي
بيانات التقرير القادم
١١ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.21
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/+10.53%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/-25.00%
Allogene Therapeutics, Inc. Common Stock earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, ALLO reported earnings of -0.19 USD per share (EPS) for Q3 25, beating the estimate of -0.22 USD, resulting in a 16.56% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.38% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 المحللين forecast an EPS of -0.21 USD, with revenue projected to reach -- USD, implying an زيادة of 10.53% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were Allogene Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Allogene Therapeutics, Inc. Common Stock reported EPS of -$0.19, beating estimates by 16.56%, and revenue of $0.00, 0% as expectations.
How did the market react to Allogene Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 12.38%, changed from $1.05 before the earnings release to $1.18 the day after.
When is Allogene Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ١١ مارس ٢٠٢٦.
What are the forecasts for Allogene Therapeutics, Inc. Common Stock's next earnings report?
Based on 16
المحللين, Allogene Therapeutics, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان